Emyria Ltd’s (ASX:EMD) Dr Michael Winlo caught up with Proactive's Andrew Scott after reporting that its clinical operations subsidiary, Emerald Clinics, has entered into a global partnership with UK-based Sapphire Medical Clinics. The partnership will provide a new source of data to bolster Emyria’s growing cannabinoid data platform and allow Emyria to leverage Sapphire’s resources and infrastructure in the UK to provide services to UK patients.
Emyria's Michael Winlo details new global partnership with UK-based Sapphire Medical Clinics
Quick facts: Emyria Ltd
Price: 0.077 AUD
Market Cap: $16.28 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Emyria Ltd named herein, including the promotion by the Company of Emyria Ltd in any Content on the Site, the Company receives from said issuer...FOR OUR FULL DISCLAIMER CLICK HERE